{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:20Z","timestamp":1791328880014,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ejphar.2015.11.028","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T13:16:10Z","timestamp":1448543770000},"page":"266-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats"],"prefix":"10.1016","volume":"769","author":[{"given":"Kiyoshi","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.11.028_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2710.2003.00491.x","article-title":"The safety of spironolactone treatment in patients with heart failure","volume":"28","author":"Anton","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejphar.2015.11.028_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib3","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1097\/01.ASN.0000033327.65390.CA","article-title":"Abolition of hypertension-induced end-organ damage by androgen receptor blockade in transgenic rats harboring the mouse ren-2 gene","volume":"13","author":"Baltatu","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/10641960500468276","article-title":"Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats","volume":"28","author":"Bayorh","year":"2006","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.ejphar.2015.11.028_bib5","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1210\/en.2005-1167","article-title":"Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats","volume":"147","author":"Buss","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2015.11.028_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.ejphar.2015.11.028_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.11.028_bib8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.11.028_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/0049825021000049277","article-title":"Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats","volume":"33","author":"Cook","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejphar.2015.11.028_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","article-title":"Antialdosterones: incidence and prevention of sexual side effects","volume":"32","author":"de Gasparo","year":"1989","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.ejphar.2015.11.028_bib11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3181\/00379727-136-35489","article-title":"Stimulation of liver microsomal drug metabolism in male and female mice by spironolactone and aldadiene","volume":"136","author":"Feller","year":"1971","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.ejphar.2015.11.028_bib12","first-page":"134","article-title":"Aldosterone, mineralocorticoid receptors, and vascular inflammation","volume":"16","author":"Fiebeler","year":"2007","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejphar.2015.11.028_bib13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.107.098012","article-title":"Mineralocorticoid receptor activation and oxidative stress","volume":"50","author":"Funder","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.11.028_bib14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/hy09t1.095762","article-title":"Hyperkalemia, renal failure, and converting-enzyme inhibition: an overrated connection","volume":"38","author":"Garc\u00eda","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.11.028_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/157340310793566109","article-title":"The DOCA-salt hypertensive rat as a model of cardiovascular oxidative and inflammatory stress","volume":"6","author":"Iyer","year":"2010","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.ejphar.2015.11.028_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","article-title":"Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability","volume":"8","author":"Karim","year":"1978","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejphar.2015.11.028_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.2042-7158.1998.tb06894.x","article-title":"Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats","volume":"50","author":"Kaukonen","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archinte.1973.00320120116008","article-title":"The role of aldosterone in renal physiology","volume":"131","author":"Knochel","year":"1973","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2015.11.028_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib20","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/etc.2330","article-title":"Cross-species sensitivity to a novel androgen receptor agonist of potential environmental concern, spironolactone","volume":"32","author":"LaLone","year":"2013","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.ejphar.2015.11.028_bib21","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","article-title":"Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions","volume":"297","author":"Lee","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2015.11.028_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/HYPERTENSIONAHA.108.111815","article-title":"Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder","volume":"52","author":"Matsui","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.11.028_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review","volume":"25","author":"Mavrakanas","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejphar.2015.11.028_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats","volume":"47","author":"Nagata","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.11.028_bib27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/FJC.0b013e3182495543","article-title":"SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats","volume":"59","author":"Nariai","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.114.221341","article-title":"DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats","volume":"354","author":"Nariai","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.11.028_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1254\/jphs.FMJ05003X3","article-title":"Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade","volume":"100","author":"Nishiyama","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.11.028_bib30","doi-asserted-by":"crossref","first-page":"R946","DOI":"10.1152\/ajpregu.00402.2006","article-title":"Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker","volume":"292","author":"Ohtani","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000101958","article-title":"Proteinuria as a therapeutic target in patients with chronic kidney disease","volume":"27","author":"Palmer","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.11.028_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.11.028_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/07435807809073634","article-title":"Plasma mineralocorticoids, plasma renin, and urinary kallikrein in salt-sensitive and salt-resistant rats","volume":"5","author":"Rapp","year":"1978","journal-title":"Endocr. Res. Commun."},{"key":"10.1016\/j.ejphar.2015.11.028_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.11.028_bib36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1524-6175.2002.01510.x","article-title":"Eplerenone: a new aldosterone receptor antagonist\u2014are the FDAs restrictions appropriate?","volume":"4","author":"Sica","year":"2002","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ejphar.2015.11.028_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2015.11.028_bib38","first-page":"597","article-title":"Androgen responsiveness and androgen receptor gene expression in human kidney cells in continuous culture","volume":"32","author":"Stefani","year":"1994","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.ejphar.2015.11.028_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/hr.2009.29","article-title":"Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension","volume":"32","author":"Takeda","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2015.11.028_bib40","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1681\/ASN.2005020129","article-title":"Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1\/2, cyclin D1, and cyclin A","volume":"16","author":"Terada","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2015.11.028_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1470320311412811","article-title":"The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease","volume":"13","author":"Tsuboi","year":"2012","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.ejphar.2015.11.028_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.15.17","article-title":"Radical scavenging properties of indapamide and renal protection in Dahl salt-sensitive rats","volume":"15","author":"Uehara","year":"1992","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2015.11.028_bib43","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1523-1755.2004.00497.x","article-title":"Testosterone promotes apoptotic damage in human renal tubular cells","volume":"65","author":"Verzola","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2015.11.028_bib44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2015.11.028_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"New Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915303691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915303691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T18:24:12Z","timestamp":1718216652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915303691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":45,"alternative-id":["S0014299915303691"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.11.028","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}